FDA cleared the Elucid PlaqueIQ from Elucid Bioimaging, Inc. on Sep 18, 2026 under K261855, a traditional 510(k). The device falls under product code LLZ, System, Image Processing, Radiological, regulated at 21 CFR 892.2050 as a Class 2 device. The review panel was Radiology.

FDA logged the submission as received on Jun 3, 2026. The decision came 107 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Elucid Bioimaging, Inc. has one other decision in the tracker over the last 12 months: K262015 (Elucid FFR-IQ (B.1)).